MoonLake Reports Strong Week 52 Sonelokimab Results in Phase 3 HS Trials

MoonLake's sonelokimab achieved 67% HiSCR75 response rate and 26% inflammatory remission at Week 52 in hidradenitis suppurativa trials, with BLA submission expected September 2026. The results position the drug as potentially best-in-class compared to competing agents, supporting advancement toward regulatory approval.